By proposing standardized estimation of aperiodic neural features and linking them to Parkinsonism and DBS modulation, the paper offers moderate translational value for developing reliable biomarkers and adaptive neuromodulation strategies, though it lacks direct molecular or therapeutic targets.

Low direct therapeutic-discovery value, but underscores the importance of patient-reported outcomes and subjective wellbeing when designing exercise interventions, safety guidance, and clinical endpoints in PD research.

While it presents no new experimental data, the paper shifts emphasis toward combination approaches that could enhance translational and repurposing potential by addressing complementary mechanisms and informing future trial design.

Although primarily a mechanistic review rather than a translational study, it highlights inflammation, microglial dysfunction, and gut–brain interactions—pathways highly relevant to Parkinson's disease—that could guide biomarker development and targeted preclinical experiments to assess therapeutic…

MIDN reveals a novel intranuclear proteasomal pathway that could be exploited to modulate disease-relevant transcriptional regulators in Parkinson's disease, offering a potentially actionable therapeutic or biomarker axis although current evidence is review-based and requires experimental…

While primarily a high‑level review with limited direct translational data, it flags BDNF and stress‑axis pathways that overlap with PD‑relevant neuroprotection and metabolic/inflammatory mechanisms, pointing to potential biomarker and repurposing hypotheses for Parkinson's therapeutic research.

The paper highlights exercise as a potentially useful symptomatic, non‑pharmacological strategy and pinpoints methodological gaps (small, heterogeneous trials, lack of PD‑specific fatigue measures) that should guide future mechanistic and sufficiently powered clinical studies, but it offers limited…

By linking ATP13A2 loss-of-function to varying levels of cellular iron overload and rescuability by wild-type protein, the work supports iron-targeted or ATP13A2-restoration therapeutic strategies and offers a more sensitive cellular biomarker approach when MRI is inconclusive for…

A Phase III-ready, non-dopaminergic small molecule targeting a novel GPCR (GPR6) has strong translational relevance and potential to provide new symptomatic or disease-modifying strategies, though the lack of an abstract limits assessment of mechanistic and biomarker data.

Moderately useful for Parkinson's therapeutic discovery because it highlights scalable, non-invasive digital biomarkers and rehabilitative interventions that can aid early detection, patient stratification, and trial endpoints, but it lacks actionable molecular mechanisms or direct therapeutic…

Provides useful surveillance of prescribing patterns, uptake of therapies, and potential gaps in real-world treatment that can guide clinical practice and health-policy decisions, but offers limited mechanistic or translational insight for novel therapeutic discovery.

By identifying emerging digital sleep biomarkers and gaps in multimodal, validated longitudinal monitoring, the paper points to opportunities to develop scalable endpoints and patient-centered phenotyping that could improve trial design and therapeutic evaluation in PD, though prospective…

By challenging simple propagation models and highlighting metabolism, network dysfunction, and limitations of nasal alpha‑syn biomarkers, the paper steers therapeutic discovery toward metabolic/neuroprotective strategies and multimodal biomarker approaches rather than focusing only on peripheral…

Although not providing new therapeutic targets, the paper outlines clinically translatable imaging biomarkers that could enable patient stratification and objective outcome measures for PD trials aimed at BBB, vascular, or inflammation-related interventions, thereby aiding translational and…

Flags constipation as a potential biomarker and modifiable gut–brain axis target that justifies monitoring and prospective intervention trials (microbiome, motility, anti-inflammatory strategies) despite the current lack of mechanistic or therapeutic evidence.

Findings inform clinical risk stratification and fall‑prevention strategies relevant to people with Parkinson's disease but provide little in the way of mechanistic insight or direct therapeutic targets for PD drug discovery.

Offers a translational, repurposing-focused strategy to combine agents with complementary mechanisms and existing safety data, which could accelerate development of multi-target disease-modifying treatments for Parkinson’s disease.

By consolidating mechanistic insights and preclinical models that tie lysosomal dysfunction and metal/polyamine homeostasis to neuronal loss, the paper highlights actionable pathways and experimental systems that can be used for target validation, biomarker development, and therapeutic screening…

By integrating genetic and immune mechanisms the paper highlights convergent, actionable biological pathways and patient‑stratification opportunities that can guide disease‑modifying therapeutic discovery and biomarker development.

While conceptual and preclinical, CAR Treg strategies offer a novel immunomodulatory approach to reduce inflammation driven by protein aggregates and could be translated into targeted therapies for Parkinson's disease if specificity, safety, and delivery challenges are resolved.

Points to a possible non-dopaminergic neurovascular contribution and an imaging biomarker for motor symptoms, but offers limited mechanistic or therapeutic actionable insight (and lacks a full abstract/primary data).

If replicated, the finding points to non-dopaminergic vascular or perfusion-related contributors and an imaging biomarker that could inform pathophysiology and patient stratification, but it offers limited immediate therapeutic targets or translational detail.

OM-MSCs represent an accessible, potentially autologous neurotrophic cell source relevant to neuroprotection/regeneration in Parkinson's, but further standardized, safety-focused and efficacy-driven studies are required before therapeutic translation.

Useful as a practical, low-risk symptomatic option for autonomic hyperhidrosis in PD, but of limited value for Parkinson's therapeutic discovery since it lacks mechanistic, biomarker, or neuroprotective relevance.

Although it doesn't target molecular disease mechanisms, the paper is moderately useful for Parkinson’s therapeutics because advances in BCI-driven, closed‑loop neuromodulation could meaningfully improve symptomatic control, personalization, and clinical translation of DBS-based interventions.